RANBP2 and hepatocellular carcinoma: Altogether, the above results consolidate the molecular mechanism of RANBP2-associated HCC malignancy, whereby its downstream SUMO target CEBPα is fundamental for OGA inactivation and subsequent hyper-O-GlcNAcylation.